U.S. Professional Services Stock News

NYSE:LAZ
NYSE:LAZCapital Markets

Lazard Taps Insider Tracy Farr As CFO To Shape 2030 Plan

Lazard (NYSE:LAZ) has appointed Tracy Farr as its new Chief Financial Officer. The leadership change is intended to support the firm's long term growth and operational efficiency plans. Farr brings extensive internal experience at Lazard to the CFO role. Lazard, traded on the NYSE under the ticker NYSE:LAZ, recently closed at $53.72. The stock has seen a 4.6% return over the past week and 10.6% over the past month, with a 62.1% return over five years. In that context, a CFO transition can...
NYSE:CAT
NYSE:CATMachinery

Caterpillar (CAT) Margin Compression Challenges Bullish Earnings Growth Narratives

Caterpillar (CAT) just turned in its FY 2025 scorecard with fourth quarter revenue of US$19.1b and basic EPS of US$5.15, alongside net income of US$2.4b. Over recent quarters, the company has seen revenue move from US$16.0b in Q3 2024 to US$17.6b in Q3 2025 and then US$19.1b in Q4 2025. Basic EPS shifted from US$5.09 to US$4.91 and then US$5.15 over the same stretch, setting up a results season where investors are weighing solid top line scale against a backdrop of compressed net margins and...
NYSEAM:CET
NYSEAM:CETCapital Markets

Central Securities (CET) Valuation After Net Asset Growth And All Time High Share Price

Central Securities (CET) has been in focus after reporting 9.3% year over year growth in net assets and higher net assets per share, alongside its stock touching an all time high of US$52.46. See our latest analysis for Central Securities. The latest share price of US$52.10 sits just below its recent all time high, and the 1 year total shareholder return of 15.44% and 5 year total shareholder return of 106.06% point to momentum that has built over time rather than fading quickly. If Central...
NasdaqGS:ONC
NasdaqGS:ONCBiotechs

Is There Now An Opportunity In BeOne Medicines (ONC) After Strong Multi‑Year Share Gains

If you are wondering whether BeOne Medicines is attractively priced right now, the key question is how its current share price stacks up against its underlying fundamentals. The stock has returned 0.3% over the last 7 days, 12.0% over 30 days, 9.4% year to date, 51.3% over 1 year and 32.5% over 3 years, while the 5 year return stands at an 8.5% decline. These moves sit against a backdrop of ongoing interest in the pharmaceuticals and biotech space, where investors often react quickly to...
NYSE:ASAN
NYSE:ASANSoftware

Assessing Asana (ASAN) Valuation After A Steady Share Price Pullback

Asana’s recent performance in focus Asana (ASAN) has been drawing attention after a weak share price stretch, with the stock showing negative returns over the past month, past 3 months, year to date, and over the past year. See our latest analysis for Asana. At a share price of $10.25, Asana’s recent 7 day share price return of a 7.99% decline and 30 day share price return of a 25.24% decline suggest fading momentum, which lines up with its 51.97% 1 year total shareholder return decline and...
NasdaqGS:OLMA
NasdaqGS:OLMABiotechs

Is It Too Late To Consider Olema Pharmaceuticals (OLMA) After Its 320% One-Year Surge?

If you are wondering whether Olema Pharmaceuticals is still priced attractively after its recent run, this article walks through the numbers in a clear, valuation focused way. The stock recently closed at US$25.72, with returns of 1.9% over 7 days, 2.9% over 30 days, 1.7% year to date and 320.9% over the past year, while the 3 year return sits at 465.3% and the 5 year return at a 45.7% decline. Recent attention on Olema has centered on its position in the pharmaceuticals and biotech space...
NYSE:WT
NYSE:WTCapital Markets

WisdomTree (WT) Earnings Growth And 20.7% Margin Test Valuation‑Skeptic Narratives

WisdomTree (WT) just posted its FY 2025 third quarter numbers, with total revenue of US$125.6 million and basic EPS of US$0.14, setting the tone with US$19.0 million in net income excluding extraordinary items. The company has seen quarterly revenue move from US$108.1 million in Q1 FY 2025 to US$112.6 million in Q2 and US$125.6 million in Q3. Basic EPS shifted from US$0.17 in Q1 and Q2 to US$0.14 in Q3, all against a trailing twelve month backdrop of US$457.0 million in revenue and EPS of...
NYSE:DCI
NYSE:DCIMachinery

How CEO Succession And Dividend Milestone At Donaldson Company (DCI) Has Changed Its Investment Story

Donaldson Company, Inc. announced that chief operating officer Richard Lewis will become president and chief executive officer and join the Board on March 2, 2026, succeeding long-serving leader Tod Carpenter, who will retire from those roles on March 1, 2026 and transition to executive chairman. The Board also declared a regular quarterly cash dividend of US$0.30 per share, extending Donaldson’s 70-year streak of uninterrupted quarterly payouts and marking the 30th consecutive year of...
NYSE:GLP
NYSE:GLPOil and Gas

Is It Time To Reassess Global Partners (GLP) After Big Five Year Share Gains?

If you are wondering whether Global Partners' share price still offers value after past gains and recent swings, starting with a clear look at its current valuation can help frame your next move. Over shorter periods the stock has had mixed returns, with 6.7% over the past week, 12.8% over the past month, 11.7% year to date, a 7.3% decline over the past year and a very large gain of about 2.4x over five years. Recent price moves sit against a backdrop of ongoing interest in energy...
NasdaqGS:TMC
NasdaqGS:TMCMetals and Mining

A Look At The Metals Company’s Valuation As Regulatory And Funding Signals Reshape Expectations

TMC the metals (TMC) is back in focus after a sharp 17.7% share price drop, as investors weigh the U.S. government’s new equity stake in USA Rare Earth against TMC’s expanded deep sea mining permit application. See our latest analysis for TMC the metals. The recent 11.85% one day share price decline, and 29.87% 7 day share price return, sit against a 30 day share price return of 7.29% and a very large 1 year total shareholder return of about 4x. This suggests momentum has cooled as investors...
NasdaqGS:MAR
NasdaqGS:MARHospitality

How Investors May Respond To Marriott International (MAR) Accelerating Global Expansion With citizenM Acquisition

In 2025, Marriott International reported strong global portfolio expansion, adding over 700 properties and nearly 100,000 rooms while growing its development pipeline and acquiring citizenM, which brought more than 35 hotels into the fold. This burst of branded growth, spanning luxury, midscale, new concepts and residences, underscores how Marriott is using brand breadth and deal-making to reinforce its long-term expansion plans. Next, we’ll examine how this acceleration in global room...